


Applications of latent variable models for data exploration and uncertainty quantification

June 21st, 2019

Melanie F. Pradier



Center for Research on
Computation and Society


at Harvard John A. Paulson School of Engineering and Applied Sciences



HDSI

Harvard Data
Science Initiative

Data everywhere!



Huge amount of opportunities...




Huge amount of opportunities...




Huge amount of opportunities...




Huge amount of opportunities...



Huge amount of opportunities...



...but still many challenges



Prognostic

Is it likely to
develop
this cancer?

Diagnostic

What type of
cancer is it?

Predictive

Is this the
optimal
drug for my
cancer?

Pharmacodynamics


What's the
optimal dose
for my body?

Recurrence


Will the
cancer
return?

Specially in high-stake decision scenarios


Bridging the gap



Bridging the gap



My research: probabilistic models for societal needs



- Design probabilistic models (modeling/inference) for real-world applications
- Crucial: multidisciplinary collaboration

My research: probabilistic models for societal needs

Highly driven by real-world application, with special emphasis on...

A) Latent Representation Learning

- *Case-control Indian Buffet Process [Pradier et.al, 2019]*
- *General Latent Feature Models [Valera et.al, 2018]*
- *Hierarchical Stick-breaking Paintbox [Pradier et.al, 2018]*

B) Uncertainty Quantification

- *Projected Bayesian Neural Networks [Pradier et.al, 2018]*
- *Poisson Process Radial Basis Function Networks [ongoing]*
- *Output-Constrained Bayesian Neural Networks [Yang et.al, 2019]*

My research: probabilistic models for societal needs

Highly driven by real-world application, with special emphasis on...

A) Latent Representation Learning

- *Case-control Indian Buffet Process [Pradier et.al, 2019]*
- *General Latent Feature Models [Valera et.al, 2018]*
- *Hierarchical Stick-breaking Paintbox [Pradier et.al, 2018]*

B) Uncertainty Quantification

- *Projected Bayesian Neural Networks [Pradier et.al, 2018]*
- *Poisson Process Radial Basis Function Networks [ongoing]*
- *Output-Constrained Bayesian Neural Networks [Yang et.al, 2019]*

Agenda from now on...



Applications of Latent Variable Models (LVMs) for:

1. Data Exploration

- Biomarker discovery in clinical trials

2. Uncertainty Quantification

- Inference framework for Bayesian neural networks




Goal 1: Data exploration

Objective: Biomarker discovery

Biomarkers used everywhere, e.g.,


- Prostate-specific antigen (PSA) to diagnose prostate cancer
- Estrogen / progesterone to predict sensitivity to endocrine therapy in breast cancer
- KRAS mutation to predict resistance to EGFr antibody treatment

Biomarker = "any variable that can be used as an indicator of a particular disease state"



Biomarker discovery is expensive

TACKLING TUMORS: Percentage of patients whose tumors were driven by certain genetic mutations that could be targets for specific drugs, by types of cancer.



Source: *Wall Street Journal* Copyright 2011 by DOW JONES & COMPANY, INC. Reproduced with permission of DOW JONES & COMPANY, INC.

ANNUAL COST OF CANCER DRUGS

New cancer medicines now routinely cost more than \$100,000 yearly, which can create hardships even for insured patients. Top 10 oncological drugs by annual cost:

Omacetaxine for chronic myeloid leukemia	\$168,366
Ibrutinib mantle cell lymphoma	\$157,440
Crizotinib non-small-cell lung cancer	\$156,544
Pomalidomide multiple myeloma	\$150,408
Regorafenib colorectal cancer	\$141,372
Sorafenib papillary thyroid cancer	\$140,984
Ponatinib chronic myeloid leukemia ¹	\$137,952
Trametinib malignant melanoma	\$125,280
Lenalidomide mantle cell lymphoma	\$124,870
Cabozantinib medullary thyroid cancer	\$118,800

Among drugs approved between 2009 and 2013 by the Food and Drug Administration


¹—Also for Ph+ acute lymphoblastic leukemia

SOURCE: JAMA Oncology, 2015

George Petras, USA TODAY

Problem formulation

Clinical trial scenario





We want to discover:

- ① Indicators of disease progression: prognostic biomarkers
- ② Indicators of (positive) drug response: predictive biomarkers



Bayesian nonparametrics

- Bayesian: to handle uncertainty $p(\Phi|\mathbf{X}) \propto p(\mathbf{X}|\Phi)p(\Phi)$
- Nonparametric: to adapt model complexity depending on input data (hypothesis generation)




Bayesian nonparametrics

- Bayesian: to handle uncertainty $p(\Phi|X) \propto p(X|\Phi)p(\Phi)$
- Nonparametric: to adapt model complexity depending on input data (hypothesis generation)



Indian Buffet Process (Ghahramani et.al, 2006)



- Prior over binary matrices with infinite number of columns
- Rows \equiv observations; columns \equiv features
- $Z \sim \text{IBP}(\alpha)$
- α : concentration parameter

Indian Buffet Process (Ghahramani et.al, 2006)

Credit: slide from F. J. R. Ruiz



Indian Buffet Process (Ghahramani et.al, 2006)


Credit: slide from F. J. R. Ruiz

	1	2	3	4	5	6	...
1	1	1	1	0	0	0	
2	1	0	1	1	0	0	
3	0	1	1	0	1	1	
:	:						

The figure illustrates the Indian Buffet Process (IBP) through a matrix representation. At the top, six different dishes are shown in small square images. Below the dishes is a horizontal ellipsis '...', indicating there are many more dishes. To the left of the matrix, three user icons are listed vertically, followed by a vertical ellipsis '...' below them, indicating there are many more users. The matrix itself has 3 rows (users) and 6 columns (dishes). The values in the matrix represent binary variables: 1 indicates that the user has tried or consumed the dish, while 0 indicates they have not. The data for the three users is as follows:

User	Dish 1	Dish 2	Dish 3	Dish 4	Dish 5	Dish 6
User 1	1	1	1	0	0	0
User 2	1	0	1	1	0	0
User 3	0	1	1	0	1	1

Infinite latent feature model (intuition)




- $x_{id} = 173 \text{ ml/dL} = 73 + 0 + 100 \text{ ml/dL}$
- $x_{nd} = 136 \text{ ml/dL} = 86 + 40 + 60 - 50 \text{ ml/dL}$

General Latent Feature Model (GLFM)

Latent feature model for heterogeneous datasets

- Link functions T_d depend on type of data for each dimension d




$$\begin{aligned}x_{nd} &= T_d(y_{nd}; \phi_d) \\y_{nd} | \mathbf{Z}, \mathbf{B} &\sim \mathcal{N}(\mathbf{Z}_{n\bullet} \mathbf{B}_{\bullet d}, \sigma_y^2) \\B_{kd} &\sim \mathcal{N}(0, \sigma_B^2) \\\mathbf{Z} &\sim \text{IBP}(\alpha)\end{aligned}$$

Open-source python code

<https://github.com/ivaleraM/GLFM>

Case-Control Indian Buffet Process (C-IBP)



R_n : drug indicator por patient n

$$x_{nd} = T_d(y_{nd}; \phi_d)$$

$$y_{nd}|Z, W, B, C, R \sim$$

$$\mathcal{N}(Z_n \bullet B_{\bullet d} + \mathbb{1}[R_n = 1] W_n \bullet C_{\bullet d}, \sigma_y^2)$$

$$B_{kd} \sim \mathcal{N}(0, \sigma_B^2)$$


$$Z \sim \text{IBP}(\alpha)$$

$$C_{kd} \sim \mathcal{N}(0, \sigma_C^2)$$

$$W \sim \text{IBP}(\alpha)$$

- **Inference:** MCMC approach with accelerated Gibbs sampling
- **Biomarker discovery:** statistical multiple hypothesis testing

Application: Immunotherapy treatment for liver cancer




[Abou-Alfa et.al, 2016]

No evidence for treatment effectiveness

Hypothesis: drug exposure as confounder

Application: Immunotherapy treatment for liver cancer



[Abou-Alfa et.al, 2016]

No evidence for treatment effectiveness

Hypothesis: drug exposure as confounder

What did we found?

- Subgroup for which treatment is especially effective
- Relevant biomarkers (drug acting as expected)



Results: subpopulations

GPC3 Antibody Treatment against Liver Cancer (J. Hepatology. 2016 Apr, Abou-Alfa et.al.)



- 180 patients: 60 took a placebo, 120 took the drug
- PFS: Progression Free Survival

Sub-population	Drug Identifier				Size (number of patients)	Mean PFS (months)	Median PFS (months)
		F1	F2	F3			
1.	0	0	0	0	33.37	3.06	1.65
2.	0	0	1	0	4.07	2.29	2.24
3.	0	1	0	0	17.84	2.72	1.81
4.	0	1	1	0	4.72	7.05	7.18
5.	1	0	0	0	51.52	3.22	2.55
6.	1	0	0	1	16.77	4.17	3.65
7.	1	0	1	0	8.38	1.74	1.33
8.	1	0	1	1	2.07	2.69	2.65
9.	1	1	0	0	29.88	3.36	2.03
10.	1	1	0	1	4.90	4.44	4.34
11.	1	1	1	0	4.53	6.31	5.31
12.	1	1	1	1	1.94	10.04	10.01

PFS (months)



Results: biomarker profiles




Take-away message:

- LVMs useful to identify hidden patterns underlying data
- Challenge addressed: data heterogeneity (both across dimensions and observations)

Goal 2: Uncertainty quantification


Two sources of uncertainty



[Depeweg et.al, 2017]

Goal 2: Uncertainty quantification


Two sources of uncertainty



[Depeweg et.al, 2017]

High-level idea


- Approximate $f_{\mathbf{w}}$ with a Bayesian Neural Network



- Modeling + inference contributions

How to estimate function uncertainty?

Gaussian Process (GP)



$$f(x) \sim \text{GP} (m(x), k(x, x'))$$


Drawbacks of GPs

- Scalability
- Kernel learning is not trivial

Alternative: Neural Networks with uncertainty

- Ensemble of Neural Networks
[Lakshminarayanan et al., 2017; Pearce et.al, 2018]
- Bayesian Neural Networks
[Buntine et al., 1991; MacKay, 1992; Neal, 1993]


Bayesian Neural Network (BNN)



$$\mathbf{y} = f_{\mathbf{w}}(\mathbf{x}) + \boldsymbol{\epsilon} \quad \mathcal{D} = \{\mathbf{x}_i, \mathbf{y}_i\}_{i=1}^N$$
$$\mathbf{w} \sim \mathcal{N}(0, \sigma_w^2 \mathbf{I}), \quad \boldsymbol{\epsilon} \sim \mathcal{N}(0, \sigma_\epsilon^2 \mathbf{I})$$

[What my deep model does not know, post of Yarin Gal, 2015]

Bayesian Neural Network (BNN)



[What my deep model does not know, post of Yarin Gal, 2015]

$$\mathbf{y} = f_{\mathbf{w}}(\mathbf{x}) + \boldsymbol{\epsilon} \quad \mathcal{D} = \{\mathbf{x}_i, \mathbf{y}_i\}_{i=1}^N$$

$$\mathbf{w} \sim \mathcal{N}(0, \sigma_w^2 \mathbf{I}), \quad \boldsymbol{\epsilon} \sim \mathcal{N}(0, \sigma_\epsilon^2 \mathbf{I})$$

Quantities of interest:

- Posterior of the weights $p(\mathbf{w}|\mathcal{D})$
- Predictive distribution

$$p(\mathbf{y}^* | \mathbf{x}^*, \mathcal{D}) = \int p(\mathbf{y}^* | \mathbf{x}^*, \mathbf{w}) p(\mathbf{w}|\mathcal{D}) d\mathbf{w}$$

$$p(w|\mathcal{D})$$

is intractable!

Inference options:

- **Markov Chain Monte Carlo**
Hamiltonian Monte Carlo [Neal, 1993]
- **Variational Inference**
[Graves, 1993] [Blundell et.al, 2015]

Variational Inference for BNNs

[Blundell et.al, 2015]


Objective: approximate $p(\mathbf{w}|\mathcal{D})$

$$q_{\lambda}(\mathbf{w}) \in \mathcal{Q}$$

$$\underset{\lambda^*}{\operatorname{argmin}} D_{\text{KL}}\left(q_{\lambda}(\mathbf{w})||p(\mathbf{w}|\mathcal{D})\right)$$



$$\underset{\lambda^*}{\operatorname{argmax}} \mathcal{L}(\lambda) = \mathbb{E}_q \left[\log p(\mathbf{y}|\mathbf{x}, \mathbf{w}) \right] - D_{\text{KL}}(q_{\lambda}(\mathbf{w})||p(\mathbf{w}))$$



Black-box VI [Ranganath et.al, 2013] + reparametrization trick [Kingma et.al, 2014; Rezende et.al, 2015]

Variational Inference for BNNs

[Blundell et.al, 2015]

Objective: approximate $p(\mathbf{w}|\mathcal{D})$


$$+ p(\mathbf{w}|\mathcal{D})$$

$$q_{\lambda}(\mathbf{w}) \in \mathcal{Q}$$

$$\underset{\lambda^*}{\operatorname{argmin}} D_{\text{KL}}(q_{\lambda}(\mathbf{w}) || p(\mathbf{w}|\mathcal{D}))$$




$$\underset{\lambda^*}{\operatorname{argmax}} \mathcal{L}(\lambda) = \mathbb{E}_q \left[\log p(\mathbf{y}|\mathbf{x}, \mathbf{w}) \right] - D_{\text{KL}}(q_{\lambda}(\mathbf{w}) || p(\mathbf{w}))$$




Black-box VI [Ranganath et.al, 2013] + reparametrization trick [Kingma et.al, 2014; Rezende et.al, 2015]

Is mean-field VI good enough?



- Several works on more flexible variational approximation families

Example on solar irradiance dataset [Gal et.al, 2015]



Related works

- Structured Variational Approximations
 - Multivariate Gaussians [Louizos et.al, 2016; Sun et.al, 2017]
 - Hierarchical Variational Models [Ranganath et.al, 2016]
- Normalizing Flows and Transformations
 - Multiplicative Normalizing Flow [Louizos et. al, 2017]
 - Hypernetworks [Krueger et.al, 2017; Pawlowski et.al, 2017]
- Ensembles of Neural Networks [Lakshminarayanan et al., 2017; Pearce et al., 2018]


Standard BNN

$$\begin{aligned}\mathbf{y} &= f_{\mathbf{w}}(\mathbf{x}) + \boldsymbol{\epsilon}, \quad \mathbf{w} \sim \mathcal{N}(0, \sigma_w^2 \mathbf{I}), \\ \boldsymbol{\epsilon} &\sim \mathcal{N}(0, \sigma_\epsilon^2 \mathbf{I})\end{aligned}$$

Weight redundancy
[Denil et.al, 2013; Frankle et.al, 2019; ...]

Projected BNN

$$\begin{aligned} \mathbf{y} &= f_{\mathbf{w}}(\mathbf{x}) + \epsilon, \quad \mathbf{w} = g_{\phi}(\mathbf{z}), \quad \mathbf{z} \sim p(\mathbf{z}), \quad \phi \sim p(\phi), \\ \epsilon &\sim \mathcal{N}(0, \sigma_{\epsilon}^2 \mathbf{I}) \end{aligned}$$



How about inference?

Objective: approximate $p(\mathbf{w}|\mathcal{D})$


$$+ p(\mathbf{w}|\mathcal{D})$$

$$q_{\lambda}(\mathbf{w}) \in \mathcal{Q}$$

$$\underset{\lambda^*}{\operatorname{argmin}} D_{\text{KL}}(q_{\lambda}(\mathbf{w}) || p(\mathbf{w}|\mathcal{D}))$$



$$\underset{\lambda^*}{\operatorname{argmax}} \mathcal{L}(\lambda) = \mathbb{E}_q \left[\log p(\mathbf{y}|\mathbf{x}, \mathbf{w}) \right] - D_{\text{KL}}(q_{\lambda}(\mathbf{w}) || p(\mathbf{w}))$$



Black-box VI [Ranganath et.al, 2013] + reparametrization trick [Kingma et.al, 2014; Rezende et.al, 2015]

How about inference?

Objective: approximate $p(\mathbf{z}, \boldsymbol{\phi} | \mathcal{D})$


$$+ p(\mathbf{z}, \boldsymbol{\phi} | \mathcal{D})$$

$$\mathbf{z} \sim q_{\boldsymbol{\lambda}_z}(\mathbf{z}), \quad \boldsymbol{\phi} \sim q_{\boldsymbol{\lambda}_{\boldsymbol{\phi}}}(\boldsymbol{\phi}), \quad \mathbf{w} = g_{\boldsymbol{\phi}}(\mathbf{z})$$

$$\underset{\boldsymbol{\lambda}^*}{\operatorname{argmin}} D_{\text{KL}}(q_{\boldsymbol{\lambda}}(\mathbf{z}, \boldsymbol{\phi}) || p(\mathbf{z}, \boldsymbol{\phi} | \mathcal{D}))$$



$$\underset{\boldsymbol{\lambda}^*}{\operatorname{argmax}} \mathcal{L}(\boldsymbol{\lambda}) = \mathbb{E}_q \left[\log p(\mathbf{y} | \mathbf{x}, g_{\boldsymbol{\phi}}(\mathbf{z})) \right] - D_{\text{KL}}(q_{\boldsymbol{\lambda}_z}(\mathbf{z}) || p(\mathbf{z})) - D_{\text{KL}}(q_{\boldsymbol{\lambda}_{\boldsymbol{\phi}}}(\boldsymbol{\phi}) || p(\boldsymbol{\phi}))$$



Black-box VI [Ranganath et.al, 2013] + reparametrization trick [Kingma et.al, 2014; Rezende et.al, 2015]

How about inference?


Objective: approximate $p(\mathbf{z}, \boldsymbol{\phi} | \mathcal{D})$

$$\mathbf{z} \sim q_{\lambda_z}(\mathbf{z}), \quad \boldsymbol{\phi} \sim q_{\lambda_\phi}(\boldsymbol{\phi}), \quad \mathbf{w} = g_\phi(\mathbf{z})$$

$$\underset{\lambda^*}{\operatorname{argmin}} D_{\text{KL}}(q_{\lambda}(\mathbf{z}, \boldsymbol{\phi}) || p(\mathbf{z}, \boldsymbol{\phi} | \mathcal{D}))$$




$$\underset{\lambda^*}{\operatorname{argmax}} \mathcal{L}(\lambda) = \mathbb{E}_q \left[\log p(\mathbf{y} | \mathbf{x}, g_\phi(\mathbf{z})) \right] - D_{\text{KL}}(q_{\lambda_z}(\mathbf{z}) || p(\mathbf{z})) - D_{\text{KL}}(q_{\lambda_\phi}(\boldsymbol{\phi}) || p(\boldsymbol{\phi}))$$



Black-box VI [Ranganath et.al, 2013] + reparametrization trick [Kingma et.al, 2014; Rezende et.al, 2015]


Extra: 3-stage Inference Framework

1. Characterize weight space



Sample multiple weight
sets [Izmailov et.al, 2018]

2. Find point estimate g_ϕ



Train an
autoencoder

3. Black-box VI (BBVI)


$$D_{\text{KL}} \left(q_\lambda(z, \phi) || p(z, \phi | \mathcal{D}) \right)$$

BBVI with smart
initialization


g_ϕ

Results


Illustrative Toy Example




(a) Projection of true weights




(b) BbB posterior over weights




(c) Proj-BNN posterior over weights



(d) Functions from true weights




(e) BbB posterior predictive




(f) Proj-BNN posterior predictive


Results: Uncertainty estimation




(a) Proj-BNN ($D_z = 2$)




(b) BbB



(c) MNF



(d) MVG




- BbB: Bayes by Back Prop [Blundell et.al, 2015]
- MVG: Multivariate Gaussians [Louizos et.al, 2016]
- MNF: Multiplicative Normalizing Flow [Louizos et. al, 2017]

GP


Results: Generalization

<https://arxiv.org/abs/1811.07006>



Results: Generalization

<https://arxiv.org/abs/1811.07006>



Open questions

- Better evaluation of uncertainty?

``Test log likelihood can be misleading''





> Entangled sources of error: model, variational approx, optimization

- How does the topology in weight space looks like?

> Intuition misleading in high dimensions!


- How to exploit latent structure for interpretability?

[Yao et. al, ICML Workshop, 2019]



Related works on weight embeddings [Karaletsos et.al, 2018; Izmailov et.al, 2019]

Conclusions



In this talk, two applications of LVMs

1. Data exploration

- a. Infinite latent feature model
for heterogeneous datasets
- b. Global and group specific factors

<https://ivaleram.github.io/GLFM/>



2. Uncertainty quantification

- a. Alternative modeling for BNNs
- b. Better approximate inference

<https://arxiv.org/abs/1811.07006>

Other projects...




Sport Science



M. F. Pradier, F. J. R. Ruiz, and F. Perez-Cruz. **Prior Design for Dependent Dirichlet Processes: An Application to Marathon Modeling**. *PlosONE*. 2016.

Other projects...



Economics



Z. Utkovski, [M. F. Pradier](#), V. Stojkoski, L. Kocarev and F. Perez-Cruz. **Economic Complexity Unfolded: An Interpretable Model for the Productive Structure of Economies**. *PlosONE*. 2018.

Other projects...

Medicine: healthcare in psychiatry



M. F. Pradier, T. H. McCoy, M. Hughes, R. H. Perlis and F. Doshi-Velez. **Predicting Treatment Discontinuation after Antidepressant Initiation**. Accepted to *Mol. Psychiatry*. 2019.

M. F. Pradier, M. Hughes, T. H. McCoy, S. Barroilhet, F. Doshi-Velez and R. H. Perlis. **Predicting Transition from Major Depression to Bipolar Disorder after Antidepressant Initiation**. Submitted to *American Journal of Psychiatry*. 2019.


From the lab to the clinic

[M. Jacobs et.al]

- Ongoing user study at MGH, Boston
 - Impact of explanations
 - Usefulness, trust...

Why are these therapies being recommended?

The following **patient features** had the highest contributions to system.13's predictions:



Which antidepressant medication would you be most likely to prescribe in this situation?



HARVARD
UNIVERSITY

Patient Details:

Jessica is a 37 year old woman who is married and works part time. She presents with 9 months of depressed mood and lack of appetite. She has a seizure disorder, and current medications include Omeprazole and Celecoxib. Prior treatment with Citalopram had no effect on depressed mood.

System.15 Recommendation: FLUOXETINE

Top 5 therapies with highest probability for stability:

Therapy	Predicted Stability*	Predicted Dropout Risk**
Fluoxetine	.76	.05
Sertraline	.67	.05
Paroxetine	.64	.10
Venlafaxine	.60	.14
Vortioxetine	.55	.15

*Stability: continued use of the same medication for at least 3 months

**Dropout: early treatment discontinuation following prescription

Why are these therapies being recommended?

The following **rules** had the highest contributions to system.15's predictions:

1. If underweight or lack of appetite, favor weight gain, favor Mirtazapine
2. If underweight or lack of appetite, avoid appetite suppressants, avoid nausea-inducing, avoid SNRI's, avoid Sertraline
3. If lack of response to Paroxetine, avoid SSRI's

Current research agenda



Impact in real-world problems:

- Personalize prescription of antidepressants
- In-vitro Fertilization

ML research questions:

- How to better quantify model uncertainty?
- How to incorporate expert knowledge?
- Which latent representations are most useful?

Contact: melanie@seas.harvard.edu

<https://melaniefp.github.io/>

Special thanks to:

- Finale Doshi-Velez
- Weiwei Pan
- Michael Hughes
- All members of dtak!
- Francisco Rodriguez Ruiz
- Fernando Perez-Cruz
- Isabel Valera
- Maria Lomeli
- Zoubin Ghahramani
- Oscar Puig
- Francesca Milletti

Thank you!



Weiwei Pan



Jiayu Yao




Soumya Ghosh



Maia Jacobs



Finale Doshi-Velez



CRCS Center for Research on
Computation and Society

at Harvard John A. Paulson School of Engineering and Applied Sciences



HDSI



Harvard Data
Science Initiative

<https://melaniefp.github.io/>

Thank you!



DtAK Lab



CRCS Center for Research on
Computation and Society

at Harvard John A. Paulson School of Engineering and Applied Sciences



HDSI

Harvard Data
Science Initiative

<https://melaniefp.github.io/>

Interpretable Machine Learning

Interpretability




- “ability to explain or to present in understandable terms to a human” (Doshi-Velez and Kim, 2017)
- requirement in the 2018 EU General Data Protection Regulation (Goodman et.al. 2016)

Interpretable Machine Learning

- Interpretable models to explain black-boxes
 - Local Interpretable Explanations (Ribeiro et.al, 2016)
 - Interpretable Decision Sets (Lakkaraju et.al, 2016)
- Interpretable models from scratch
 - Tree-regularization of deep models (Wu et.al, 2017)
 - Input-gradient regularization (Ross et.al, 2017)

In this talk, interpretability via prob. graphical models


Results: Generalization (Ablations)




1-stage			
linear			
$q(z)$ only			$q_{\lambda_z}(z)$

Cross-validation of latent dimension

<https://arxiv.org/abs/1811.07006>



Statistical methodology for biomarker discovery



M. F. Pradier, B. Reis, L. Jukofsky, F. Milletti, T. Ohtomo, F. Perez-Cruz, and O. Puig. **Case-control Indian Buffet Process identifies biomarkers of response to Codrituzumab.** *BMC Cancer.* 2019.

Prediction-constrained Autoencoder

$$\begin{aligned} \{\boldsymbol{\theta}^*, \boldsymbol{\phi}^*\} = \operatorname{argmin}_{\boldsymbol{\theta}, \boldsymbol{\phi}} \mathcal{L}(\boldsymbol{\theta}, \boldsymbol{\phi}) &= \min_{\boldsymbol{\theta}, \boldsymbol{\phi}} \left\{ \frac{1}{R} \sum_{r=1}^R \left(\mathbf{w_c}^{(r)} - g_{\boldsymbol{\phi}} \left(f_{\boldsymbol{\theta}} \left(\mathbf{w_c}^{(r)} \right) \right) + \gamma^{(r)} \right)^2 \right. \\ &\quad \left. + \beta \mathbb{E}_{(x,y) \sim \mathcal{D}} \left[\frac{1}{R} \sum_{r=1}^R \log p(y|x, g_{\boldsymbol{\phi}} \left(f_{\boldsymbol{\theta}} \left(\mathbf{w_c}^{(r)} \right) \right)) \right] \right\}, \end{aligned}$$

My research: probabilistic models for societal needs

Highly driven by real-world application, with special emphasis on...

A) Latent Representation Learning

M. F. Pradier, B. Reis, L. Jukofsky, F. Milletti, T. Ohtomo, F. Perez-Cruz, and O. Puig. **Case-control Indian Buffet Process identifies biomarkers of response to Codrituzumab.** *BMC Cancer*. 2019.

I. Valera, M. F. Pradier, M. Lomeli, and Z. Ghahramani. **General Latent Feature Models for Heterogeneous Datasets.** *In submission to Journal of Machine Learning Research*. 2018.

M. F. Pradier, W. Pan, M. Yau, R. Singh, and F. Doshi-Velez. **Hierarchical Stick-breaking Paintbox.** *BNP@NeurIPS Workshop*. Montreal (Canada), December 2018.

B) Uncertainty Quantification

M. F. Pradier, W. Pan, J. Yao, S. Ghosh, and F. Doshi-Velez. **Projected BNNs: Avoiding Pathologies in Weight Space by projecting Neural Network Weights.** Arxiv. 2019.

B. Coker, M. F. Pradier, and F. Doshi-Velez. **Poisson Process Radial Basis Function Networks.** (Arxiv coming soon)

W. Yang, L. Lorch, M. A. Graule, S. Srinivasan, A. Suresh, J. Yao, M. F. Pradier, and F. Doshi-Velez. **Output-Constrained Bayesian Neural Networks.** *ICML Workshop on Generalization*. 2019.